hematopoiet
stem
cell
transplant
treatment
choic
mani
hematolog
malign
genet
diseas
howev
viral
infect
continu
account
substanti
posttranspl
morbid
mortal
antivir
drug
avail
virus
associ
signific
side
effect
frequent
ineffect
review
focus
immunotherapeut
strategi
use
prevent
treat
infect
past
year
outlin
differ
refin
introduc
goal
move
therapi
beyond
special
academ
center
overal
studi
demonstr
adopt
transfer
allodeplet
cell
feasibl
mean
hasten
immun
reconstitut
prevent
treat
viral
infect
howev
effici
allodeplet
vari
impact
vivo
safeti
antivir
control
incid
gvhd
altern
strategi
neutral
alloantigenspecif
cell
render
anerg
approach
reli
requir
cell
hlarestrict
antigenspecif
signal
second
costimulatori
signal
becom
activ
prolifer
thu
anergi
induc
block
interact
cell
tzannou
leen
hematopoiet
stem
cell
transplant
hsct
cur
varieti
malign
nonmalign
hematolog
condit
congenit
diseas
howev
seriou
viral
infect
remain
major
caus
morbid
respons
mortal
increas
array
virus
implic
posttranspl
infecti
complic
due
part
comprehens
patient
screen
use
improv
detect
method
also
extens
therapeut
modal
higherrisk
patient
ie
individu
without
human
leukocyt
antigen
hla
match
sibl
donor
receiv
extens
manipul
product
andor
prolong
immunosuppress
thu
reactiv
latent
virus
includ
cytomegaloviru
cmv
epsteinbarr
viru
ebv
herp
simplex
viru
hsv
human
herpesviru
varicella
zoster
viru
human
herpesviru
bk
viru
bkv
frequent
infect
associ
array
communityacquir
respiratori
virus
includ
influenza
parainfluenza
metapneumoviru
adenoviru
adv
respiratori
syncyti
viru
rsv
increasingli
report
tcell
therapi
restor
virusspecif
immun
hsct
set
viabl
altern
tradit
often
toxic
antivir
drug
explor
immunotherapeut
strategi
current
use
provid
immedi
longterm
antivir
protect
adultand
pediatrichsct
patient
first
adopt
tcell
transfer
approach
util
allogen
hsct
set
involv
adopt
transfer
unmanipul
donor
lymphocyt
term
donor
lymphocyt
infus
dli
dli
therapi
base
assumpt
unmanipul
lymphocyt
isol
seroposit
donor
contain
popul
virusspecif
cell
abl
expand
vivo
provid
antivir
protect
dli
proven
effect
treat
ebvassoci
posttranspl
lymphoprolif
diseas
ebvptld
adv
urinari
tract
infect
cmv
reactiv
encephalopathi
persist
rsv
pneumonia
howev
efficaci
approach
limit
low
circul
frequenc
cell
direct
mani
acut
virus
substanti
higher
frequenc
alloreact
cell
within
infus
product
significantli
increas
risk
caus
graft
versu
host
diseas
gvhd
thu
order
preserv
benefit
minim
risk
associ
dli
infus
techniqu
select
deplet
alloreact
cell
induc
anergi
investig
ex
vivo
allodeplet
involv
select
remov
cell
alloreact
potenti
prior
adopt
transfer
order
identifi
particular
tcell
subset
donor
cell
first
expos
recipientderiv
antigenpres
cell
apc
includ
peripher
blood
mononuclear
cell
pbmc
activ
cell
ebvtransform
lymphoblastoid
cell
line
ebvlcl
dendrit
cell
dc
andor
fibroblast
subsequ
cell
alloactiv
upregul
marker
hladr
prolifer
allow
physic
remov
magnet
bead
apoptosisinduc
chemotherapi
immunotoxin
photodynam
purg
date
immunotoxin
photodynam
purg
use
clinic
montagna
colleagu
deplet
alloreact
cell
use
murin
monoclon
antibodi
coupl
deglycosyl
ricin
chain
dga
via
crosslink
smpt
preclin
studi
montagna
et
al
demonstr
cocultur
patient
pbmc
irradi
haploident
haplo
donor
pbmc
follow
exposur
result
cell
popul
retain
virusspecif
precursor
exhibit
diminish
cytolyt
activ
patient
bone
marrow
base
result
andreschmutz
colleagu
perform
phase
iii
clinic
studi
allodeplet
cell
kg
infus
pediatr
haplo
match
unrel
donor
mud
hsct
recipi
day
posttranspl
despit
absenc
gvhd
prophylaxi
case
grade
iiiiv
gvhd
report
compar
favor
rate
grade
ii
acut
gvhd
patient
infus
unmanipul
dli
cellskg
furthermor
infus
cell
appear
provid
antivir
protect
patient
activ
infect
immun
reconstitut
acceler
absolut
tcell
number
l
within
week
three
patient
activ
cmv
patient
persist
adv
one
refractori
ebvptld
abl
clear
infect
postinfus
allodeplet
also
use
adult
hsct
set
solomon
colleagu
infus
recipi
matchedrel
donor
mrd
transplant
follow
reduc
intens
condit
median
allodeplet
donor
cellskg
rang
kg
agvhd
grade
iiv
occur
rate
grade
iiiiv
gvhd
reduc
compar
rate
report
previou
studi
final
group
also
investig
safeti
antivir
activ
allodeplet
cell
demonstr
dose
cellskg
requir
promot
antivir
immun
reconstitut
vivo
altern
method
allodeplet
photodynam
purg
involv
exposur
alloactiv
cell
phototox
dye
dye
permeat
activ
nonactiv
cell
select
retain
activ
subset
due
inactiv
multidrugresist
pump
pglycoprotein
confer
cell
sensit
visibl
light
nm
induc
mitochondri
oxid
cell
death
assess
potenc
approach
clinic
mielk
colleagu
infus
hlaident
sibl
hsct
recipi
year
photodepleteddonor
cellskg
day
transplant
engraft
rapid
patient
unfortun
incid
acut
chronic
c
gvhd
high
probabl
develop
agvhd
grade
iiiv
cgvhd
furthermor
complic
associ
viral
patient
reactiv
cmv
two
patient
develop
bkassoci
hemorrhag
cystiti
adv
n
bk
adv
n
patient
die
rsv
pneumon
bacteri
invas
fungal
infect
unexpectedli
frequent
sever
result
earli
termin
trial
investig
indic
high
gvhd
rate
like
due
poor
alloactiv
achiev
matcheds
set
photodeplet
process
preferenti
deplet
memori
cell
includ
popul
respons
provid
protect
infect
thu
ongo
studi
photodeplet
util
haplo
set
preliminari
result
encourag
patient
develop
agvhd
grade
apc
first
clinic
phase
studi
exploit
method
perform
davi
et
al
pediatr
adult
patient
highrisk
hematolog
malign
bone
marrow
failur
receiv
haplo
hsct
patient
receiv
bone
marrow
graft
contain
median
cellskg
rang
kg
follow
ex
vivo
treatment
n
antibodi
n
evalu
patient
develop
grade
iii
n
iv
n
agvhd
patient
develop
cgvhd
substanti
lower
histor
control
addit
major
infus
patient
count
month
reconstitut
cell
includ
virusspecif
precursor
shown
detect
cmv
ebv
pentamerposit
popul
inde
five
patient
reactiv
cmv
four
clear
viru
within
day
receiv
antivir
medic
administ
donor
cell
transgen
modifi
express
suicid
gene
trigger
vivo
event
gvhd
altern
ex
vivo
allodeplet
although
varieti
suicid
system
test
preclin
hsv
thymidin
kinas
hsvtk
induc
caspas
util
clinic
hsvtk
modifi
cell
abl
phosphoryl
nontox
prodrug
ganciclovir
ganciclovir
monophosph
convert
triphosph
form
cellular
kinas
incorpor
dna
result
chain
termin
cell
death
hsvtk
ganciclovir
system
also
caus
cell
death
induc
express
receptor
selfaggreg
lead
format
deathinduc
signal
complex
prospect
nonrandom
multicent
phase
iii
trial
highrisk
leukemia
patient
age
year
receiv
haplo
hsct
follow
subject
monthli
infus
hsvtk
cell
rang
kg
day
posttranspl
hsvtk
cell
infus
well
toler
administr
cell
dose
kg
support
posttranspl
immun
reconstitut
defin
circul
tcell
number
greater
equal
detect
two
consecut
occas
occur
median
day
posttcel
administr
inde
cmvand
ebvspecif
immun
infus
patient
could
detect
within
month
posttranspl
interestingli
first
wave
circul
tk
cell
major
cell
support
longterm
immun
reconstitut
carri
suicid
gene
display
naiv
phenotyp
suggest
hsvtk
infus
abl
drive
recoveri
thymic
activ
adult
individu
develop
agvhd
grade
iiv
cgvhd
receiv
ganciclovir
exhibit
signific
reduct
p
circul
frequenc
tkdirect
cell
resolut
gvhd
show
transgen
function
notabl
patient
frequenc
hsvtk
neg
lymphocyt
unaffect
p
virusspecif
tcell
activ
diminish
data
suggest
patient
gvhd
without
viral
infect
activ
suicid
switch
result
select
deplet
alloreact
cell
leav
virusreact
popul
untouch
despit
result
concern
hsvtk
platform
cell
kill
restrict
divid
cell
induct
cell
death
may
requir
sever
day
factor
limit
clinic
benefit
approach
furthermor
depend
ganciclovir
prodrug
preclud
use
treatment
posthsct
viral
infect
final
virusderiv
hsvtk
gene
immunogen
lead
unintent
elimin
engin
cell
especi
rel
immunocompet
recipi
inde
aforement
trial
seven
patient
infus
late
rang
week
hsct
develop
tkdirect
tcell
respons
group
util
suicid
gene
system
platform
activ
administr
chemic
induc
dimer
cid
bioinert
small
moleculewhich
lead
rapid
cell
death
cell
death
h
postcid
ten
haplo
hsct
recipi
year
infus
cell
rang
cellskg
day
posttranspl
four
patient
develop
grade
ii
gvhd
follow
singl
infus
cid
circul
frequenc
transgen
cell
decreas
within
min
drug
administr
gvhd
rapidli
resolv
without
recurr
despit
subsequ
reexpans
residu
transgen
cell
remark
residu
transgen
cell
capabl
provid
antivir
benefit
demonstr
three
patient
whose
endogen
virusspecif
cell
control
cmv
reactiv
n
adv
infect
n
furthermor
like
hsvtk
infus
cell
appear
promot
endogen
immun
reconstitut
evidenc
detect
naiv
cell
thymic
origin
evid
immun
respons
transgen
cell
infus
treg
also
propos
immunotherapeut
approach
suppress
alloact
hsct
patient
work
found
observ
patient
receiv
graft
donor
low
absolut
treg
number
median
rang
greater
risk
develop
gvhd
receiv
graft
donor
higher
number
treg
median
rang
subsequ
rezvani
colleagu
postul
select
expans
infus
donor
treg
time
transplant
could
reduc
risk
gvhd
without
affect
virusspecif
tcell
activ
brunstein
et
al
establish
method
posit
select
treg
cryopreserv
third
parti
partial
hla
match
hla
match
umbil
cord
blood
ucb
use
clinic
grade
magnet
microbead
follow
select
cell
expand
day
ex
vivo
presenc
antibodyco
bead
result
median
increas
cell
rang
contain
median
rang
cell
suppress
effect
result
product
demonstr
mix
lymphocyt
reaction
ratio
treg
dct
cell
result
suppress
prolifer
rang
subsequ
approach
test
clinic
phase
clinic
trial
recipi
median
age
year
doubl
ucb
transplant
receiv
either
one
day
n
two
day
n
infus
third
partyderiv
ucb
treg
dose
rang
kg
histor
control
receiv
treg
incid
tzannou
grade
iiiv
agvhd
rate
gvhd
reduc
despit
potenti
indiscrimin
tregassoci
immunosuppress
effect
risk
viral
infect
increas
contrari
reduc
risk
infect
vs
control
group
di
ianni
colleagu
also
evalu
activ
adopt
transfer
treg
initi
studi
haplo
hsct
recipi
receiv
dli
product
rang
cellskg
fresh
treg
cellskg
isol
donor
apheresi
product
first
deplet
cell
follow
select
cell
treg
appear
protect
gvhd
sinc
evalu
patient
develop
agvhd
grade
ii
among
five
receiv
highest
dli
dose
moreov
cell
infus
associ
acceleratedimmun
reconstitut
pathogenspecif
cell
detect
earli
month
posttranspl
compar
previous
report
month
timefram
infus
also
correl
reduc
incid
cmv
reactiv
diseas
rel
convent
haplo
hsct
recipi
n
studi
suggest
adopt
immunotherapi
treg
limit
alloreact
without
compromis
immun
reconstitut
antigenspecif
tcell
respons
altern
strategi
provid
posthsct
antivir
protect
infus
virusspecif
cell
vst
either
isol
directli
peripher
blood
select
expand
ex
vivo
enrich
virusdirect
popul
consequ
reduct
residu
alloreact
cell
date
two
direct
select
method
test
clinic
multim
select
captur
multim
select
reli
abil
cell
bind
complex
peptideload
hla
molecul
via
tcell
receptor
captur
techniqu
isol
cell
base
abil
secret
follow
antigen
stimul
tabl
multim
selectionmultim
complex
peptideload
hla
molecul
label
fluoresc
tag
magnet
bead
use
specif
select
cell
reactiv
present
peptid
cobbold
colleagu
first
use
approach
clinic
treat
cmv
reactiv
posttranspl
use
panel
tetram
complex
four
peptideload
hla
molecul
direct
hla
hla
peptid
select
cmvdirect
tcell
precursor
donor
peripher
blood
cell
infus
nine
recipi
mrd
n
mud
n
transplant
cmv
viremia
within
h
select
despit
low
number
exclus
cell
infus
median
tetramerselect
cellskg
rang
kg
cmvspecif
cell
becam
detect
patient
within
day
transfer
expand
vivo
clear
infect
eight
nine
case
uhlin
colleagu
subsequ
use
higher
avid
pentam
complex
five
hla
molecul
direct
panel
peptid
ebv
cmv
adv
select
vst
frozen
donor
graft
n
haploident
third
parti
peripher
blood
n
select
cell
rang
cellskg
safe
infus
eight
hsct
patient
age
year
ebvptld
n
cmv
reactiv
n
adv
infect
n
posttransf
infus
cell
detect
earli
day
persist
day
five
six
evalu
patient
furthermor
infus
associ
clinic
benefit
within
week
decreas
viral
titer
patient
receiv
donorderiv
cell
four
six
patient
treat
third
parti
cell
tetramerspentam
bind
cell
irrevers
give
rise
multipl
concern
clinic
use
includ
potenti
induc
immun
respons
vivo
toxic
furthermor
number
group
report
chang
tcell
phenotyp
follow
multim
engag
induct
toler
even
apoptosi
address
concern
knabel
colleagu
develop
next
gener
multimer
complex
call
streptam
streptam
easili
dissoci
tcell
receptor
addit
dbiotin
caus
multim
monomer
detach
cell
within
second
leav
select
popul
phenotyp
function
ident
unmanipul
cell
figur
clinic
donorderiv
streptamerselect
cell
use
treat
two
adult
mud
hsct
recipi
refractori
cmv
infect
patient
receiv
total
hla
cmv
tcellskg
patient
infus
tcellskg
singl
infus
frequenc
cmvspecif
cell
increas
maximum
cell
patient
patient
cell
donorderiv
result
endogen
reconstitut
demonstr
analysi
donor
chimer
tcell
receptor
excis
circl
pcr
infus
safe
result
persist
clearanc
cmv
antigenemia
preclin
investig
minimum
number
cell
requir
vivo
benefit
stemberg
colleagu
use
murin
listeria
monocytogen
infect
model
demonstr
even
singl
epitopespecif
tcell
abl
prolifer
differenti
effector
centralmemori
tcell
subset
could
provid
pathogenspecif
effect
subsequ
group
administ
cell
per
kilogram
respect
two
pediatr
haplo
hsct
recipi
refractori
cmv
infus
cell
becam
detect
peripheri
day
postinfus
respect
transit
less
differenti
matur
differenti
effector
popul
vivo
concurr
decreas
patient
viral
load
studi
demonstr
feasibl
efficaci
safeti
multimerselect
cell
vivo
howev
approach
appli
immunolog
wellcharacter
virus
date
restrict
cell
captureth
captur
approach
select
cell
base
abil
secret
effector
cytokin
respons
antigen
stimul
thu
approach
neither
peptid
hla
restrict
figur
strategi
success
use
prevent
treat
adv
cmv
ebv
infect
hsct
recipi
feuchting
colleagu
first
use
advdirect
cell
treat
nine
pediatr
age
year
recipi
mud
n
mismatch
mm
ud
n
mrd
n
haplo
n
transplant
system
adv
infect
n
diseas
n
isol
cell
repres
mix
cell
infus
day
posttranspl
dose
rang
cellskg
infus
well
toler
singl
report
skin
cgvhd
aggrav
expand
vivo
control
infectionsdiseas
five
six
evalu
patient
group
also
treat
patient
age
month
year
refractori
cmv
infect
n
diseas
n
mrd
haplo
mud
mmud
hsct
use
method
cell
reactiv
infus
mean
day
posttranspl
side
effect
gvhd
infus
cell
expand
vivo
overal
patient
clear
signific
reduct
viral
load
postinfus
includ
two
patient
enceph
pegg
colleagu
report
similar
success
use
cmvcaptur
cell
prophylact
n
preemptiv
n
phase
iii
clinic
trial
studi
despit
infus
small
cell
number
median
cmvspecif
cellskg
respect
infus
cell
provid
antivir
protect
one
prophylacticallyinfus
patient
requir
antivir
drug
within
next
month
furthermor
preemptiv
infus
patient
requir
brief
antivir
drug
administr
day
instanc
reactiv
ebv
reactiv
also
sensit
therapi
shown
moosmann
et
al
use
ebvpeptid
pool
contain
epitop
peptid
ebv
antigen
five
latent
four
earli
lytic
two
late
lytic
stimul
ebvspecif
cell
donorperipher
blood
leukapheres
six
adult
biopsyproven
ebvptld
unrespons
convent
treatment
receiv
singl
dose
select
cell
cellskg
three
patient
earlystag
diseas
transfer
cell
expand
vivo
detect
pentam
stain
elispot
produc
complet
remiss
howev
profil
three
patient
latestag
ptld
multiorgan
failur
differ
tcell
expans
detect
clinic
respons
final
icheva
colleagu
target
universallyexpress
latent
protein
infus
reactiv
cell
mean
cellskg
ten
pediatr
adult
patient
age
year
refractori
ebv
viremia
ptld
day
posthsct
observ
vivo
expans
transfer
cell
eight
ten
patient
seven
clinic
virolog
respons
defin
decreas
viral
load
greater
one
log
resolut
ptld
studi
demonstr
captur
success
select
polyclon
cell
use
prevent
treat
even
refractori
adv
cmv
ebv
infect
posthsct
howev
similar
multim
select
method
appli
virus
high
frequenc
circul
specif
cell
virus
immunogenicprotect
antigen
identifi
altern
strategi
prepar
virusenrich
tcell
fraction
specif
expand
popul
ex
vivo
repetit
stimul
antigenload
apc
result
loss
cell
alloreact
potenti
tabl
cytomegaloviruscmv
first
viru
specif
target
use
ex
vivo
expand
cell
walter
colleagu
use
fibroblast
infect
strain
cmv
stimul
pbmc
expand
either
antibodi
cmvinfect
fibroblast
autologousfeed
cell
result
vst
administ
prophylact
hlaident
hsct
recipi
four
weekli
escal
dose
start
day
posttranspl
infusionrel
toxic
note
mild
gvhd
grade
iii
report
three
patient
remark
none
infus
patient
develop
cmv
viremia
diseas
patient
also
demonstr
increas
circul
frequenc
cmvspecif
cell
postinfus
howev
patient
without
endogen
cmvspecif
cell
cell
number
rapidli
declin
highlight
import
helper
tcell
subset
vivo
subsequ
einsel
colleagu
use
altern
method
prepar
polyclon
cmvdirect
vst
incub
donorderiv
pbmc
cmv
lysat
day
follow
restimul
cmv
antigen
irradi
autolog
feeder
cell
four
stimul
final
product
contain
virusspecif
mean
mean
cell
lack
alloreact
even
donor
recipi
mismatch
three
hla
allel
eight
recipi
mrd
mmrd
mud
mmud
transplant
ganciclovirresist
cmv
treat
singl
dose
cmvspecif
cellsm
median
day
posthsct
rang
day
infus
well
toler
report
gvhd
seven
evalu
patient
signific
reduct
greater
one
log
cmvdna
durabl
five
two
patient
highest
viral
load
decreas
cmvdna
transient
howev
second
infus
suffici
produc
sustain
viral
clearanc
patient
patient
refus
second
infus
eventu
succumb
hisher
infect
phase
iiiii
studi
pegg
colleagu
administ
cmvst
prophylact
preemptiv
high
risk
hsct
recipi
infus
prophylact
cell
appear
protect
sinc
incid
cmv
reduc
compar
histor
control
furthermor
patient
receiv
preemptiv
tcell
therapi
infus
cell
expand
substanti
vivo
produc
viral
clearanc
final
blyth
colleagu
report
result
phase
ii
clinic
trial
allogen
transplant
recipi
age
year
prophylact
infus
cellsm
cmvst
line
gener
dc
puls
cmv
peptid
nlv
n
transfect
adenovir
vector
genet
modifi
express
n
although
infus
reduc
frequenc
cmv
reactiv
percentag
patient
requir
antivir
drug
durat
treatment
decreas
studi
popul
vs
vs
day
respect
data
studi
suggest
cmvspecif
cell
st
mediat
direct
antivir
effect
also
reduc
requir
antivir
therapi
correspond
reduct
drug
diseaseassoci
morbid
transplant
cost
apc
set
sinc
transform
b
cell
express
antigen
profil
malign
cell
therebi
maxim
therapeut
benefit
expand
tcell
line
date
transplant
recipi
age
month
year
mean
year
infus
ebvst
prevent
n
tcell
deplet
hsct
n
high
risk
lymphoproliph
diseas
treat
biopsyproven
probabl
ebvptld
n
none
patient
infus
prophylact
develop
ebvptld
compar
incid
histor
control
cohort
furthermor
first
patient
receiv
vst
genet
mark
neomycinresist
gene
allow
us
track
cell
year
postinfus
demonstr
adopt
transfer
cell
acquir
memori
phenotyp
like
natur
memori
ebv
cell
abl
surviv
longterm
expand
upon
antigen
stimul
final
patient
proven
probabl
diseas
time
ebvst
treatment
complet
sustain
clinic
respons
result
recapitul
numer
center
includ
memori
sloan
ketter
karolinska
institut
univers
pavia
howev
rare
treatment
failur
also
taught
import
lesson
exampl
dubrovina
colleagu
report
three
nonrespond
patient
infus
tcell
line
recogn
donorderiv
lcl
transform
ebv
laboratorystrain
viru
strain
ebv
express
patient
tumor
group
report
similar
phenomenon
patient
fail
respond
ebvst
later
found
harbor
tumor
viru
delet
gene
remov
immunodomin
epitop
exclus
target
infus
line
case
highlight
import
infus
polyclon
cell
reactiv
multipl
antigensepitop
express
endogen
tumor
ensur
clinic
benefit
attempt
target
one
multipl
clinic
problemat
virus
simultan
group
develop
strategi
gener
biand
trivirusdirect
vst
specif
advebv
cmv
seroneg
donor
advebvcmv
multispecif
cell
activ
use
monocyt
transduc
chimer
vector
biviru
follow
weekli
stimul
autolog
ebvlcl
transduc
vector
figur
biand
triviru
line
polyclon
show
activ
target
virus
base
elispot
cytotox
assay
though
triviru
product
cmvspecif
fraction
domin
total
patient
age
year
safe
infus
infus
prophylactiv
therapeut
howev
adv
detect
increas
specif
cell
patient
activ
infect
highlight
import
antigen
stimul
vivo
expans
note
none
infus
patient
develop
de
novo
adv
infect
compar
incid
similar
pediatr
transplant
recipi
absenc
vst
therapi
suggest
infus
cell
persist
expand
follow
stimul
provid
longterm
protect
adenovir
diseas
multispecif
cell
also
associ
clinic
benefit
induc
partial
complet
respons
three
patient
cmv
reactiv
includ
one
refractori
case
six
patient
ebv
includ
patient
ebvptld
five
patient
adv
infect
reduc
manufactur
time
avoid
use
live
viru
viral
vector
next
investig
whether
viral
antigenencod
dna
plasmid
could
use
expand
antigenspecif
cell
use
amaxa
nucleofect
system
plasmidnucleofect
dc
use
activ
antigenspecif
tcell
popul
triviru
specif
total
day
consist
abl
gener
vst
similar
phenotyp
specif
function
profil
tradit
gener
trivirusdirect
cell
cell
safe
infus
ten
patient
cmv
n
ebv
n
adv
n
infect
produc
complet
respons
includ
four
patient
dual
infect
recent
extend
spectrum
antigen
target
use
singl
tcell
line
includ
ebv
cmv
adv
also
bkv
studi
manufactur
process
simplifi
substitut
clinic
grade
pepmix
peptid
overlap
plasmid
allow
direct
stimul
pbmc
antigen
activ
follow
day
grex
devic
figur
clinic
multiviru
vst
produc
mix
cell
specif
reflect
donor
serostatu
exampl
donor
cmv
seroneg
lack
cmvreactiv
tcell
compon
etc
nevertheless
major
line
gener
recogn
least
three
virus
eleven
line
administ
recipi
mrd
n
mud
n
mmud
n
haplo
n
transplant
dose
rang
cellsm
either
prophylaxi
n
treat
one
four
viral
infect
n
despit
receiv
singl
vitro
stimul
infus
mvst
exhibit
safeti
profil
similar
extens
expand
tcell
product
furthermor
cell
produc
clinic
respons
patient
ebv
n
cmv
n
n
adv
n
infectionsreactiv
six
seven
patient
bkv
infect
complet
partial
respons
defin
reduct
baselinevir
load
improv
clinic
signssymptom
respons
includ
four
patient
symptomat
tissu
involv
ebvptld
n
bkvcystiti
n
data
demonstr
product
broad
spectrum
vst
feasibl
provid
safe
effect
antivir
protect
section
illustr
rel
simplic
associ
prepar
virusspecif
cell
seroposit
donor
howev
isol
cell
either
seroneg
donor
ucb
substanti
challeng
given
low
circul
precursor
frequenc
virusreact
cell
phenotyp
henc
activ
expand
naiv
cell
vitro
one
requir
profession
apc
well
potent
cytokin
nevertheless
test
whether
vst
preventtreat
posttranspl
infect
hanley
colleagu
gener
triviru
vst
cmv
ebv
adv
fraction
cord
blood
unit
infus
seven
cord
blood
transplant
recipi
dose
rang
cellsm
infus
well
toler
earli
subsequ
gvhd
protect
five
patient
treat
prophylact
two
remain
patient
cmv
adv
infect
respect
abl
clear
virus
even
though
second
vst
infus
requir
patient
cmv
thu
earli
report
suggest
ucbderiv
vst
promot
virusdirect
immun
reconstitut
vivo
despit
safeti
profil
clear
clinic
benefit
associ
adopt
transfer
vst
therapi
still
restrict
select
academ
center
special
good
manufactur
practic
infrastructur
expertis
requir
individu
product
problemat
transplant
donor
seroneg
case
urgent
need
address
issu
util
bank
shelf
vst
gener
transplantelig
donor
investig
howev
sourc
immedi
avail
one
must
also
consid
potenti
greater
risk
gvhd
associ
infus
line
mismatch
one
hla
loci
nevertheless
haqu
colleagu
gener
test
activ
thirdparti
ebvst
solid
organ
transplant
two
hsct
recipi
refractori
biopsyproven
ebvptld
line
infus
chosen
basi
hla
match
vitro
cytotox
ebv
patient
receiv
product
match
two
five
hla
allel
four
weekli
dose
cellskg
infus
well
toler
refractori
patient
result
clinic
respons
week
month
subsequ
analysi
demonstr
level
hla
match
correl
outcom
month
overal
better
respons
rate
p
followup
studi
vicker
colleagu
infus
line
match
allel
patient
ebvptld
post
solid
organ
transplant
n
hsct
n
eight
ten
evalu
patient
achiev
complet
remiss
includ
four
patient
cn
diseas
oreilli
colleagu
also
report
result
five
patient
ebvptld
treat
thirdparti
line
four
complet
respond
final
group
util
bank
cell
specif
cmv
ebv
adv
treat
patient
refractori
cmv
adv
andor
ebv
infect
posthsct
eighti
two
hsct
transplant
recipi
screen
particip
studi
suitabl
linebas
overal
level
hla
match
presenc
tcell
activ
infect
viru
share
hla
allel
identifi
individu
bank
product
total
line
infus
patient
sever
refractori
infect
cmv
n
adv
n
ebvptld
n
marrow
n
peripher
blood
n
cord
blood
n
transplant
despit
low
level
hla
match
rang
match
allel
de
novo
gvhd
occur
two
patient
grade
case
achiev
respons
three
virus
target
cumul
respons
rate
week
postinfus
cmv
adv
ebv
respect
major
durabl
overal
studi
demonstr
despit
initi
concern
infus
thirdparti
vst
safe
clinic
benefici
justifi
broader
implement
approach
tabl
major
caus
posttranspl
morbid
mortal
relaps
infect
sinc
donorderiv
vst
abl
expand
persist
longterm
without
induc
gvhd
group
recent
also
explor
possibl
provid
dual
antivir
antitumor
activ
genet
modifi
vst
express
tumortarget
chimer
antigen
receptor
car
inde
cruz
colleagu
modifi
trivirusspecif
cell
car
direct
administ
eight
patient
posit
bcell
malign
age
year
post
mrd
mud
transplant
infusionrel
toxic
gvhd
sinc
cell
genemodifi
quantit
pcr
use
track
transgen
popul
persist
median
week
blood
week
diseas
site
two
evalu
patient
correl
object
clinic
respons
moreov
carvst
retain
antivir
activ
vivo
sinc
two
patient
reactiv
ebv
concomit
increas
frequenc
circul
ebvspecif
precursor
elispot
qpcr
signal
suggest
virusinduc
expans
thu
pilot
studi
demonstr
feasibl
confer
vst
abil
target
tumorexpress
antigen
provid
preliminari
evid
support
use
singl
product
prevent
relaps
infect
viral
infect
increas
caus
morbid
mortal
follow
hsct
tcell
therapi
reconstitut
antivir
immun
beyond
doubt
clinic
safe
effect
treatment
strategi
use
rapid
isol
techniqu
possibl
select
virusspecif
popul
infus
within
hour
expans
protocol
util
prepar
cell
bank
infus
donorspecif
thirdparti
set
final
sinc
current
mvst
manufactur
platform
accommod
addit
specif
one
consid
extend
immunotherapeut
protect
clinic
problemat
virus
includ
jc
influenza
parainfluenza
human
metapneumoviru
coronaviru
rsv
bocaviru
provid
broad
spectrum
antivir
protect
virusspecif
cell
crucial
provid
protect
viral
infect
post
allogen
hematopoiet
stem
cell
transplant
infus
donor
lymphocyt
infus
provid
antivir
benefit
coincid
risk
graft
versu
host
diseas
gvhd
due
presenc
alloreact
cell
risk
gvhd
mitig
inactiv
alloreact
cell
infus
select
virusspecif
cell
broad
spectrum
antivir
protect
provid
singl
tcell
line
simultan
specif
multipl
virus
cell
bank
administ
shelf
product
partial
human
leukocyt
antigenmatch
recipi
provid
clinic
benefit
tabl
clinic
trial
use
directli
isol
virusspecif
cell
prophylaxi
treatment
number
patient
multim
select
cmv
tabl
clinic
trial
use
ex
vivo
expand
virusspecif
cell
tabl
clinic
trial
use
third
parti
virusspecif
cell
immunotherapi
author
manuscript
avail
pmc
june
